newsfilter.io

Isla Garraway

Showing 1–2 of 2 transcripts.

  1. Milken Institute1h 0m

    Advancing Critical Health Issues for Veterans

    Jonathan Simons, Prudence Fisher, Isla Garraway, Deborah Lafer Scher, Earle Mack, Peter O'Rourke, Arock Bolanos, Christopher Seeley, Gary, Debra, Major Kent

    Hosted by Dr. Jonathan Simons of the Prostate Cancer Foundation, this panel outlines a strategic public-private partnership designed to modernize Veterans Health Administration care through precision oncology and innovative mental health interventions. Key initiatives include a $50 million commitment to establish a national network of Centers of Excellence for prostate cancer genome sequencing and a standardized equine therapy trial targeting PTSD, which leverages biofeedback mechanisms to reduce suicide risks among the 30% of veterans diagnosed with the disorder. By addressing critical infrastructure bottlenecks and utilizing the Million Veterans Program's genetic database, these collaborative models aim to create scalable, evidence-based healthcare solutions for veterans that can subsequently be extended to the broader civilian population.

  2. Milken Institute1h 1m

    The Promise of the Cancer Moonshot

    Kathy Hudson, Anna Barker, L. Michelle Bennett, Robert Bradway, Louis DeGennaro, Isla Garraway, Lou DiGennaro, Greg Simon, Tom Caleo, Jackie Brandwin, Greg Zuckerman, Laura Kalmos Nasser, Mike Hiltik, Noah Crafts

    Following the Vice President's appointment to lead "Mission Control" and a proposed $1 billion federal funding request, the Cancer Moonshot initiative seeks to accelerate cancer research by prioritizing patient outcomes over bureaucratic processes. The program targets a structural shift from competition to collaboration through new mandates for data sharing, the launch of the Genomic Data Commons, and the implementation of patient-centric clinical trial designs. By leveraging public-private partnerships and modernizing regulatory frameworks, the initiative aims to bridge the gap between clinical trial success and real-world health equity within a 15-month timeline.